Skip to content
S1196Senate2023-2024 SessionSame asA1673

Require Biomarker Testing Coverage

Official title

“Requires health insurance policies and medicaid to cover biomarker testing for certain purposes”

Sponsor Roxanne J. PersaudSD-19+33 co-sponsorsAffects Finance
Status
Signed by Governor
Impact
8/10
Significant
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill requires health insurance and Medicaid in New York to cover biomarker testing for diagnosis, treatment, and monitoring of diseases.

Why it matters

  1. Expands Access to Precision Medicine. By mandating coverage for biomarker testing, the bill could enable more patients to receive personalized treatments—especially in cancer care and other diseases where targeted therapies depend on specific biological markers.

  2. Reduces Barriers to Timely Diagnosis and Treatment. The law requires insurers and Medicaid to streamline processes for coverage exceptions and minimize the need for repeated biopsies or sample collections, potentially speeding up access to appropriate care and reducing patient burden.

  3. Standardizes Coverage Based on Latest Science. Insurance coverage decisions must align with FDA approvals, Medicare coverage determinations, and nationally recognized clinical guidelines, helping ensure that patients in New York have access to up-to-date, evidence-based diagnostic tools.

  4. Addresses Health Equity. By including Medicaid and requiring parity in coverage whether services are provided directly or through managed care, the bill aims to ensure that low-income and vulnerable populations benefit equally from advances in biomarker testing.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Biomarker Testing Coverage

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Approval memo.76
  2. Signed chap.754
  3. Delivered to governor
  4. Returned to senate
  5. Passed assembly
  6. Ordered to third reading rules cal.679
  7. Substituted for A1673A
  8. Referred to ways and means
  9. Delivered to assembly
  10. Passed senateVote 61–0
  11. Ordered to third reading cal.1451
  12. Committee discharged and committed to rules
Show 4 earlier actions
  1. Print number 1196a
  2. Amend and recommit to finance
  3. Reported and committed to finance
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A1673Assembly

Require Insurance for Biomarker Tests

Assembly Floor Calendar · Sponsor Pamela J. Hunter

Impact 8 · Significant0% to pass

Full text

5 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1196--A

2023-2024 Regular Sessions

IN SENATE

January 10, 2023

Introduced by Sens. PERSAUD, ADDABBO, BROUK, CHU, CLEARE, COMRIE, COONEY, GALLIVAN, GIANARIS, GONZALEZ, GOUNARDES, GRIFFO, HARCKHAM, HELMING, HOYLMAN-SIGAL, KENNEDY, KRUEGER, MANNION, MATTERA, MAY, MYRIE, PALUMBO, PARKER, RIVERA, SALAZAR, SCARCELLA-SPANTON, SERRANO, SKOUFIS, STAVISKY, THOMAS, WEIK -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- reported favorably from said committee and committed to the Committee on Finance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law and the social services law, in relation to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 11-c to read as follows:

(11-c) (A) Every policy which provides medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(ii) centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(iii) nationally recognized clinical practice guidelines such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02625-06-3

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D) As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.

(ii) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multiplex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) "Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 11-c to read as follows:

(11-c) (A) Every insurer delivering a group or blanket policy or issuing a group or blanket policy for delivery in this state that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(ii) centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(iii) nationally recognized clinical practice guidelines including, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D) As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.

(ii) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multiplex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) "Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 3. Section 4303 of the insurance law is amended by adding a new subsection (p-1) to read as follows:

(p-1) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to:

(A) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(B) centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(C) nationally recognized clinical practice guidelines such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.

(2) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(3) The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this subsection. Such process shall be made readily accessible on the website of the insurer.

(4) As used in this subsection, the following terms shall have the following meanings:

(A) "Biomarker" means a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.

(B) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multiplex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(C) "Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(D) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 4. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (mm) to read as follows:

(mm) (i) biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a recipient's disease or condition when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to:

(1) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(2) centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(3) nationally recognized clinical practice guidelines such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.

(ii) Risk-bearing entities contracted to the medicaid program to deliver services to recipients shall provide biomarker testing at the same scope, duration and frequency as the medicaid program otherwise provides to enrollees.

(iii) The recipient and participating provider shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy of the medicaid program or by risk-bearing entities contracted to the medicaid program. Such process shall be made readily accessible to all participating providers and enrollees online.

(iv) As used in this paragraph, the following terms shall have the following meanings:

(1) "Biomarker" means a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.

(2) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multiplex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(3) "Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(4) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 5. This act shall take effect April 1, 2024 and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the social services law, in relation to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes

Purpose or general idea of bill

This legislation will require that every state-regulated insurance plan, including Medicaid, provide coverage for biomarker testing when medically appropriate.

Summary of provisions

Section 1 requires every individual accident and health insurance policy that provides coverage for medical, major medical, or similar comprehen- sive-type coverage shall provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition. Defines criteria for what types of medical and scientific evidence qualify as sufficient medical and scientific evidence for biomarker testing.

Section 2 applies these same provisions to group or blanket accident and health insurance policies

Section 3 applies these same provisions to all hospital service corpo- ration or health service corporation

Section 4 applies these same provisions to Medicaid

Section 5 provides for the effective date

Justification

In cancer care, biomarkers are often used to help determine the best treatment for a patient. A "biomarker" is a sign of disease or abnormal function that can be measured in blood, tissue, or bodily fluid. Biomarker testing is the analysis of a patient's tissue, blood or fluid biospecimen for the presence of a biomarker.

Progress in improving cancer outconkies increasingly involves the use of precision medicihe. Biomarker testing is an important step for accessing precision medicine, including targeted therapies that can improve survi- vorship and better cancer patients' quality of life. Biomarker testing is increasingly important for cancer care and for the treatment of other diseases. Thirty- seven of the 62 oncology drugs launched in the past five years require or recommend biomarker testing before use.

This legislation will ensure New Yorkers covered by state-regulated insurance plans, including Medicaid, have coverage for biomarker testing when medically appropriate.

Improving access to biomarker testing and thereby access to targeted therapies is a strategy to reduce health disparities and improve outcomes for cancer patients.

Ensuring equitable access to biomarker testing by improving coverage for and access to testing across insurance types is key to reducing health disparities. Indeed, without action like this to expand coverage for biomarker testing - including Medicaid - advances in precision oncology could increase existing health disparities.

Legislation to expand coverage of biomarker testing in New York would make it possible for more patients to get the proper treatment at the right time.

Prior legislative history

2022: S8147 Referred to Insurance

Fiscal implications

Any cost of enacting this legislation is far overshadowed by ensuring that the course of treatment used in treating an individual patient's cancer is the most effective and cost-effective treatment.

Effective date

This act shall take effect April 1, 2024.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.